patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_695762 | REC_0011801 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.2 | 68 | male | 1 | 5 | 4.8 | 5 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:59.815883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579839 | REC_0011802 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 8.6 | 73 | female | 3 | 32 | 5.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.7 | false | MSS | 2026-03-15T05:35:59.816151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900423 | REC_0011803 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.9 | 66 | female | 0 | 20 | 5.8 | 3 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:59.816391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146515 | REC_0011804 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.3 | 68 | female | 1 | 17 | 4.2 | 5 | osimertinib 80 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:59.816625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944235 | REC_0011805 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 6.7 | 74 | female | 1 | 22 | 3 | 1 | alectinib 600 mg BID | 17.4 | false | MSS | 2026-03-15T05:35:59.816914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205146 | REC_0011806 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 8.4 | 75 | female | 1 | 18 | 5.5 | 0 | entrectinib 600 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:59.817146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599923 | REC_0011807 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 13 | 61 | male | 1 | 7 | 4.7 | 5 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:35:59.817382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400203 | REC_0011808 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 4.2 | 55 | male | 1 | 18 | 4.4 | 9 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:35:59.817615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538037 | REC_0011809 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.7 | 59 | male | 0 | 31 | 5.4 | 2 | pembrolizumab 200 mg q3w | 21.3 | true | MSS | 2026-03-15T05:35:59.817846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539061 | REC_0011810 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 6 | 72 | female | 2 | 19 | 4.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 28.3 | true | MSS | 2026-03-15T05:35:59.818075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336126 | REC_0011811 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 10.2 | 64 | male | 1 | 18 | 4.3 | 6 | alectinib 600 mg BID | 10 | true | MSS | 2026-03-15T05:35:59.818309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768022 | REC_0011812 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 5 | 65 | female | 1 | 16 | 6.5 | 2 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:59.818538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295146 | REC_0011813 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 16 | 82 | female | 1 | 10 | 5.4 | 4 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:59.818771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365810 | REC_0011814 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 9.6 | 72 | male | 2 | 11 | 4.6 | 1 | alectinib 600 mg BID | 8.2 | true | MSS | 2026-03-15T05:35:59.819001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621848 | REC_0011815 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.3 | 63 | male | 0 | 11 | 5.7 | 6 | osimertinib 80 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:59.819233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626188 | REC_0011816 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 2.8 | 65 | male | 0 | 74 | 3.8 | 1 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:35:59.819464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416249 | REC_0011817 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.6 | 71 | female | 0 | 34 | 3.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.819694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461148 | REC_0011818 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 8.6 | 73 | female | 3 | 9 | 5.2 | 1 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:59.819964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646316 | REC_0011819 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.8 | 90 | male | 1 | 12 | 6.8 | 8 | entrectinib 600 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:59.820232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543471 | REC_0011820 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.4 | 65 | male | 0 | 5 | 5.4 | 5 | osimertinib 80 mg daily | 13.4 | false | MSI-H | 2026-03-15T05:35:59.820471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332679 | REC_0011821 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.2 | 68 | female | 1 | 24 | 7 | 2 | alectinib 600 mg BID | 13.6 | false | MSS | 2026-03-15T05:35:59.820699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287137 | REC_0011822 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.3 | 48 | female | 0 | 49 | 7.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:59.820931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388565 | REC_0011823 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.4 | 69 | female | 0 | 14 | 5.7 | 1 | osimertinib 80 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:59.821166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482713 | REC_0011824 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 9.1 | 87 | female | 1 | 3 | 3.6 | 6 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.821392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379052 | REC_0011825 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.6 | 79 | female | 2 | 14 | 4.2 | 4 | alectinib 600 mg BID | 17 | false | MSS | 2026-03-15T05:35:59.821627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767073 | REC_0011826 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 5.4 | 64 | female | 0 | 17 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.2 | false | MSS | 2026-03-15T05:35:59.821858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895549 | REC_0011827 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.9 | 64 | male | 1 | 15 | 5.5 | 9 | alectinib 600 mg BID | 12.3 | true | MSI-H | 2026-03-15T05:35:59.822095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831021 | REC_0011828 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 18 | 5.5 | 71 | male | 2 | 15 | 6.3 | 3 | pembrolizumab 200 mg q3w | 11.4 | false | MSS | 2026-03-15T05:35:59.822325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331422 | REC_0011829 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 8.2 | 57 | male | 1 | 32 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:59.822557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109407 | REC_0011830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.2 | 71 | female | 1 | 9 | 5.1 | 5 | entrectinib 600 mg daily | 19 | false | MSS | 2026-03-15T05:35:59.822789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470305 | REC_0011831 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 8.8 | 79 | male | 1 | 51 | 4.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.7 | false | MSS | 2026-03-15T05:35:59.823063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855021 | REC_0011832 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 15.8 | 72 | female | 2 | 8 | 3.8 | 4 | alectinib 600 mg BID | 6.1 | true | MSS | 2026-03-15T05:35:59.823296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620835 | REC_0011833 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 17.5 | 79 | female | 1 | 10 | 6.6 | 6 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:59.823528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121007 | REC_0011834 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 17.4 | 63 | female | 0 | 18 | 5.5 | 2 | osimertinib 80 mg daily | 18.6 | true | MSS | 2026-03-15T05:35:59.823763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617406 | REC_0011835 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 8.9 | 70 | male | 2 | 11 | 5.8 | 1 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:35:59.824002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248872 | REC_0011836 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10 | 78 | female | 1 | 17 | 3.7 | 8 | entrectinib 600 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.824314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809828 | REC_0011837 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.3 | 58 | male | 0 | 23 | 6.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 24.6 | false | MSS | 2026-03-15T05:35:59.824568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212995 | REC_0011838 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 14.2 | 75 | female | 2 | 16 | 7.3 | 0 | entrectinib 600 mg daily | 43.1 | false | MSS | 2026-03-15T05:35:59.824820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520704 | REC_0011839 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 16.4 | 76 | male | 2 | 12 | 6 | 2 | pembrolizumab 200 mg q3w | 22.9 | false | MSI-H | 2026-03-15T05:35:59.825070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374191 | REC_0011840 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 19 | 20.3 | 55 | male | 1 | 18 | 6.3 | 0 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:59.825316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892547 | REC_0011841 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.5 | 66 | female | 0 | 10 | 8.5 | 2 | osimertinib 80 mg daily | 20.9 | false | MSI-H | 2026-03-15T05:35:59.825561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853416 | REC_0011842 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 21.6 | 77 | female | 1 | 27 | 4 | 6 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:59.825810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133565 | REC_0011843 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.4 | 63 | male | 0 | 6 | 4.5 | 1 | osimertinib 80 mg daily | 15.3 | true | MSI-H | 2026-03-15T05:35:59.826055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580100 | REC_0011844 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.4 | 61 | male | 1 | 5 | 6.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:35:59.826424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134850 | REC_0011845 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 6.2 | 63 | male | 1 | 10 | 6.1 | 5 | sotorasib 960 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.826692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233637 | REC_0011846 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.3 | 68 | male | 0 | 17 | 7.7 | 7 | alectinib 600 mg BID | 7.3 | false | MSI-H | 2026-03-15T05:35:59.826962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789611 | REC_0011847 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 10.8 | 69 | male | 0 | 19 | 4.5 | 2 | alectinib 600 mg BID | 13.8 | true | MSS | 2026-03-15T05:35:59.827211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267656 | REC_0011848 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.8 | 63 | male | 1 | 7 | 4.6 | 1 | alectinib 600 mg BID | 20.3 | false | MSI-H | 2026-03-15T05:35:59.827447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178395 | REC_0011849 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 15 | 70 | male | 0 | 20 | 6.3 | 2 | entrectinib 600 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:59.827698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386508 | REC_0011850 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 15.2 | 62 | female | 1 | 13 | 5.6 | 1 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:59.827974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661143 | REC_0011851 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 11 | 8.5 | 72 | female | 2 | 7 | 6.5 | 5 | sotorasib 960 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:59.828258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696495 | REC_0011852 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.5 | 73 | female | 3 | 9 | 6.3 | 4 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.828499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217301 | REC_0011853 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 7.4 | 53 | male | 0 | 18 | 6.6 | 2 | entrectinib 600 mg daily | 24 | false | MSS | 2026-03-15T05:35:59.828737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132492 | REC_0011854 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.2 | 60 | female | 1 | 14 | 4.5 | 7 | osimertinib 80 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:59.828970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764203 | REC_0011855 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17 | 64 | female | 0 | 16 | 5.6 | 6 | alectinib 600 mg BID | 6.9 | false | MSI-H | 2026-03-15T05:35:59.829207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328000 | REC_0011856 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.8 | 85 | female | 2 | 40 | 5 | 6 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:35:59.829433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336259 | REC_0011857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 15 | 7.1 | 70 | female | 2 | 27 | 5.7 | 6 | alectinib 600 mg BID | 5.3 | true | MSS | 2026-03-15T05:35:59.829752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812667 | REC_0011858 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 6.3 | 54 | male | 0 | 53 | 6.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 4.3 | true | MSS | 2026-03-15T05:35:59.829996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195227 | REC_0011859 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14.7 | 74 | female | 1 | 5 | 3.9 | 2 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:59.830249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669068 | REC_0011860 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.1 | 77 | male | 2 | 20 | 6.5 | 2 | sotorasib 960 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:59.830537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874262 | REC_0011861 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.2 | 76 | female | 2 | 98 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.6 | true | MSS | 2026-03-15T05:35:59.830767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275448 | REC_0011862 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 9.8 | 60 | female | 0 | 14 | 4.2 | 7 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.831060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377934 | REC_0011863 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.4 | 72 | female | 1 | 22 | 8.3 | 2 | osimertinib 80 mg daily | 16.9 | false | MSI-H | 2026-03-15T05:35:59.831299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756136 | REC_0011864 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 19.9 | 57 | female | 0 | 17 | 6.3 | 1 | alectinib 600 mg BID | 36.7 | true | MSS | 2026-03-15T05:35:59.831585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557193 | REC_0011865 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 8 | 60 | female | 1 | 9 | 5.2 | 1 | entrectinib 600 mg daily | 25.4 | false | MSS | 2026-03-15T05:35:59.831821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197304 | REC_0011866 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 13.7 | 68 | female | 1 | 13 | 6.3 | 2 | pembrolizumab 200 mg q3w | 18.5 | false | MSS | 2026-03-15T05:35:59.832163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269988 | REC_0011867 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 10.3 | 60 | female | 1 | 19 | 6.9 | 2 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:59.832407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709349 | REC_0011868 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 16.2 | 67 | female | 1 | 12 | 5.5 | 0 | osimertinib 80 mg daily | 23.4 | true | MSI-H | 2026-03-15T05:35:59.832643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705701 | REC_0011869 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 17.4 | 51 | female | 0 | 19 | 6.3 | 3 | alectinib 600 mg BID | 22.9 | false | MSI-H | 2026-03-15T05:35:59.832902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442390 | REC_0011870 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.7 | 81 | female | 1 | 15 | 5.8 | 4 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.833200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432912 | REC_0011871 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 17.5 | 77 | female | 1 | 0 | 4.9 | 8 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:59.833437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783595 | REC_0011872 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 3.6 | 63 | male | 0 | 36 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.3 | false | MSS | 2026-03-15T05:35:59.833670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993239 | REC_0011873 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 19.6 | 71 | male | 1 | 15 | 8.3 | 3 | entrectinib 600 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:59.833907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646896 | REC_0011874 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.7 | 63 | female | 1 | 45 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:35:59.834138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800717 | REC_0011875 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7 | 90 | male | 1 | 7 | 3.7 | 4 | entrectinib 600 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:59.834382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416298 | REC_0011876 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10 | 58 | male | 1 | 11 | 6 | 1 | osimertinib 80 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:35:59.834618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345024 | REC_0011877 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 18.5 | 75 | female | 0 | 17 | 5.9 | 4 | sotorasib 960 mg daily | 6.3 | false | MSS | 2026-03-15T05:35:59.834879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279445 | REC_0011878 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 9.4 | 60 | male | 0 | 3 | 9.5 | 1 | sotorasib 960 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:59.835126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797824 | REC_0011879 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 12.9 | 67 | female | 0 | 20 | 4.2 | 5 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.835386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354327 | REC_0011880 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 13.7 | 48 | female | 0 | 12 | 6.8 | 1 | entrectinib 600 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:59.835626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137624 | REC_0011881 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.3 | 79 | female | 2 | 38 | 5.4 | 6 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:35:59.835869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252961 | REC_0011882 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.7 | 74 | female | 0 | 10 | 5.8 | 4 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:59.836249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264977 | REC_0011883 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 16.2 | 69 | female | 0 | 21 | 6.6 | 4 | osimertinib 80 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:59.836589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449529 | REC_0011884 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14.2 | 57 | female | 0 | 15 | 5.8 | 1 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:59.836839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803524 | REC_0011885 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 13.7 | 68 | male | 0 | 10 | 4.3 | 5 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:59.837079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225695 | REC_0011886 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.6 | 75 | female | 1 | 31 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.1 | true | MSS | 2026-03-15T05:35:59.837309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683585 | REC_0011887 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 16.1 | 67 | female | 0 | 23 | 6.1 | 6 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:35:59.837545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931562 | REC_0011888 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.2 | 78 | female | 2 | 17 | 3.5 | 6 | osimertinib 80 mg daily | 7 | true | MSS | 2026-03-15T05:35:59.837781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723484 | REC_0011889 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 10.8 | 62 | female | 1 | 4 | 6.7 | 1 | sotorasib 960 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:59.838018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454189 | REC_0011890 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.6 | 65 | female | 1 | 16 | 4.9 | 6 | sotorasib 960 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:59.838253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801046 | REC_0011891 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 10.7 | 75 | female | 2 | 23 | 4.7 | 3 | pembrolizumab 200 mg q3w | 15.2 | false | MSS | 2026-03-15T05:35:59.838496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240041 | REC_0011892 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.2 | 67 | female | 1 | 11 | 4.7 | 5 | osimertinib 80 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:59.838727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659466 | REC_0011893 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.8 | 60 | male | 1 | 13 | 7.2 | 6 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:59.838960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937044 | REC_0011894 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 9.2 | 58 | male | 1 | 49 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:35:59.839193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475061 | REC_0011895 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 8.1 | 68 | female | 0 | 18 | 5.8 | 1 | osimertinib 80 mg daily | 19.6 | false | MSS | 2026-03-15T05:35:59.839435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393174 | REC_0011896 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 15 | 57 | female | 1 | 11 | 5.2 | 2 | osimertinib 80 mg daily | 21.9 | true | MSI-H | 2026-03-15T05:35:59.839728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150081 | REC_0011897 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.2 | 68 | female | 0 | 17 | 5 | 2 | sotorasib 960 mg daily | 22.1 | true | MSI-H | 2026-03-15T05:35:59.839976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432716 | REC_0011898 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.5 | 64 | male | 1 | 30 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.9 | true | MSS | 2026-03-15T05:35:59.840244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816921 | REC_0011899 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.4 | 52 | female | 0 | 12 | 4.7 | 5 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:59.840480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915192 | REC_0011900 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 19.2 | 60 | female | 1 | 14 | 5.4 | 6 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:59.840721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.